
Alembic Pharmaceuticals delivered exceptional financial results for Q2 FY27, with consolidated profit after tax surging 81.1% year-on-year to ₹335 crore compared to ₹185 crore in the corresponding quarter last year. According to the latest company press release, sequentially, the profit jumped 94% from ₹173 crore posted at the end of the June quarter. The company's revenue from operations increased 36.3% year-on-year to ₹2,604 crore in Q2 FY27, up from ₹1,910 crore in Q2 FY26. EBITDA rose 78.4% year-on-year to ₹563.3 crore, with the EBITDA margin expanding sharply to 21.6% from the previously reported 16.5% in the year-ago period. However, the latest earnings report shows EBITDA margin improved further to 22% in the September quarter, demonstrating continued operational efficiency gains.
The international business segment showed remarkable performance, with US formulations revenue increasing 77% to ₹1,003 crore during the quarter. As reported by NDTV Profit, the company launched three products in the US market during Q2 FY27, contributing significantly to this growth. The ex-US business grew 12% year-on-year to ₹440 crore, while Alembic received one abbreviated new drug application (ANDA) approval, bringing its cumulative ANDA approvals to 245. The company's active pharmaceutical ingredients (API) business reported 39% year-on-year growth in revenue to ₹436 crore. The company's US revenue has grown at a CAGR of 7% over FY22-FY26, increasing from ₹16.66 billion in FY22 to ₹22.06 billion in FY26.
In the domestic market, Alembic Pharmaceuticals' India branded business reported revenue of ₹725 crore, registering 14% year-on-year growth during the quarter. According to Business Standard, Managing Director Pranav Amin noted that improving momentum in chronic therapies is strengthening the quality of growth in the India branded business. The company is seeing encouraging traction across its existing US branded portfolio, with the ex-US and API businesses also continuing to grow. As reported in the latest earnings, the India Branded Business reported 14% YoY growth in revenue to ₹725 crore, with the company's gynaecology, cardiology, gastroenterology and ophthalmology segments registering robust growth. The Animal Health business continued its growth momentum, recording a 23% increase during the quarter.
Shares of Alembic Pharmaceuticals rallied as much as 20% following the strong quarterly results announcement, hitting the 20% upper circuit limit of ₹965 on the NSE against its last closing price. As reported by NDTV Profit, the stock later pared some gains to trade 13.23% higher at ₹910.50 per share on the NSE, compared to a 0.47% advance to the Nifty index. The strong performance came despite the broader market's modest gains, with the stock showing significant outperformance during the trading session. Managing Director Pranav Amin commented on the results, stating that the company delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Following a strong first half, the company is well positioned to sustain growth and create long-term value for all stakeholders.